Literature DB >> 12384809

Characterisation of tumour-associated antigens in colon cancer.

Aija Line1, Zane Slucka, Aivars Stengrevics, Karina Silina, Geng Li, Robert C Rees.   

Abstract

In order to search for clinically relevant cancer-associated genes and to define further the spectrum of immunogenic proteins, we applied SEREX (serological identification of antigens by recombinant expression cloning) to analyse genes expressed in colon adenocarcinoma. Eight different serum-reactive cDNA clones were isolated by immunoscreening from a colon cancer-derived cDNA expression library. mRNA expression studies showed that 2 of them, RHAMM and AD034, have a differential tissue distribution, and that 3 genes, NAP1L1, RHAMM and AD034, are overexpressed in tumours in comparison with the adjacent non-cancerous tissues. 5' RLM-RACE analysis of AD034, a sequence with a tyrosine kinase motif, revealed a frameshifting insertion of 32 bp, most likely generated by use of cryptic splice site in tumour-derived cDNA. Analysis of full-length RHAMM cDNA sequence revealed the presence of two splice variants, which are known to have a different sub-cellular localisation; expression of these splice variants is altered in colon cancer tissues. Serological responses to three antigens (C21ORF2, EPRS and NAP1L1) were found mainly in cancer patients' sera.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384809     DOI: 10.1007/s00262-002-0322-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  Next generation modeling in GWAS: comparing different genetic architectures.

Authors:  Evangelina López de Maturana; Noelia Ibáñez-Escriche; Óscar González-Recio; Gaëlle Marenne; Hossein Mehrban; Stephen J Chanock; Michael E Goddard; Núria Malats
Journal:  Hum Genet       Date:  2014-06-17       Impact factor: 4.132

Review 2.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

Review 3.  Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers.

Authors:  Hideo Shigeishi; Koichiro Higashikawa; Masaaki Takechi
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-28       Impact factor: 4.553

Review 4.  Usage of cancer associated autoantibodies in the detection of disease.

Authors:  Steven P Dudas; Madhumita Chatterjee; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 5.  Genes involved in neuroendocrine tumor biology.

Authors:  Eva Hofsli
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 6.  Immune-epithelial crosstalk at the intestinal surface.

Authors:  Nadine Wittkopf; Markus F Neurath; Christoph Becker
Journal:  J Gastroenterol       Date:  2014-01-28       Impact factor: 7.527

7.  De Novo proteome analysis of genetically modified tumor cells by a metabolic labeling/azide-alkyne cycloaddition approach.

Authors:  Seda Ballikaya; Jennifer Lee; Uwe Warnken; Martina Schnölzer; Johannes Gebert; Jürgen Kopitz
Journal:  Mol Cell Proteomics       Date:  2014-09-15       Impact factor: 5.911

8.  RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability.

Authors:  Christopher A Maxwell; Jonathan J Keats; Mary Crainie; Xuejun Sun; Tim Yen; Ellen Shibuya; Michael Hendzel; Gordon Chan; Linda M Pilarski
Journal:  Mol Biol Cell       Date:  2003-03-20       Impact factor: 4.138

9.  First siRNA library screening in hard-to-transfect HUVEC cells.

Authors:  Markus Zumbansen; Ludger M Altrogge; Nicole Ue Spottke; Sonja Spicker; Sheila M Offizier; Sandra Bs Domzalski; Allison L St Amand; Andrea Toell; Devin Leake; Herbert A Mueller-Hartmann
Journal:  J RNAi Gene Silencing       Date:  2009-10-29

10.  The transforming acidic coiled coil (TACC1) protein modulates the transcriptional activity of the nuclear receptors TR and RAR.

Authors:  Romain Guyot; Séverine Vincent; Julie Bertin; Jacques Samarut; Patrick Ravel-Chapuis
Journal:  BMC Mol Biol       Date:  2010-01-15       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.